// App-Quantinova.ai

: Finerenone and chronic kidney disease outcomes in Black patients with type 2 diabetes: A FIDELITY analysis

Researchers

Presenter

  • John M. Flack

Principal Investigators

  • Rajiv Agarwal

  • Stefan D. Anker

  • Bertram Pitt

  • Luis M. Ruilope

  • Peter Rossing

  • Sharon Alder

  • Linda Fried

  • Kenneth Jamerson

  • Robert Toto

  • Meike Brinker

  • Alfredo E. Farjat

  • Peter Kolkhof

  • Amer Joseph

  • George Bakris

Medical Centers

  • Bayer, Berlin, Germany

  • Harbor UCLA Medical Center, Torrance, California, United States

  • Bayer, Reading, United Kingdom.

  • UTSW Medicine, Dallas, United States

  • 1Bayer, Wuppertal, Germany.

  • Institute of Research i, Madrid, Spain

  • RFUMS/Chicago Med Schl, North Chicago, IL, United States

  • University of Copenhagen, Copenhagen E, Denmark

  • 1 Indiana Uni., Indianapolis, United States

  • Southern Illinois Uni., Springfield, United States

  • Charité, Berlin, Germany.

  • U Michigan, Ann Arbor, Michigan, United States

Locations

  • Germany

  • United Kingdom

  • Spain

  • United States

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Nephrology

  • Genetic Disorder

Disease

  • Chronic kidney disease

  • Type 2 diabetes mellitus

  • Renal disease

  • Diabetes

Biomarkers

  • N/A

Drug/Treatment

  • Finerenone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved